Melanoma Clinical Trial

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Summary

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.

View Eligibility Criteria

Eligibility Criteria

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen
During cohort expansion, subjects with advanced cancer that either have received at least one prior therapy or are treatment naive, depending on the specified tumor type
Subjects must have measurable disease
Subject must consent to provide previously collected tumor tissue and a tumor biopsy during screening.
At least 4 weeks since any previous treatment for cancer
Must be able to swallow pills or capsules
Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1

Exclusion Criteria:

Active or chronic autoimmune diseases
Uncontrolled or significant cardiovascular disease
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma)
Active central nervous system (CNS) metastases and CNS metastases as the only sites of disease
Active infection

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

627

Study ID:

NCT02658890

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 47 Locations for this study

See Locations Near You

University of Arizona Cancer Center
Tucson Arizona, 85724, United States
Local Institution - 0026
La Jolla California, 92093, United States
Local Institution - 0035
Tampa Florida, 33612, United States
Emory Winship Cancer Institute
Atlanta Georgia, 30322, United States
Northside Hospital, Inc
Atlanta Georgia, 30342, United States
Local Institution - 0027
Chicago Illinois, 60637, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Lutherville Maryland, 21093, United States
Barbara Ann Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Local Institution - 0006
Saint Louis Missouri, 63110, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
New York University
New York New York, 10016, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
Local Institution - 0034
Philadelphia Pennsylvania, 19111, United States
UPMC Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
St Vincent'S Hospital (Nsw)
Darlinghurst Australian Capital Territory, 2010, Australia
Local Institution - 0045
North Sydney New South Wales, 2146, Australia
Local Institution
Westmead New South Wales, 2145, Australia
Princess Alexandra Hospital
Brisbane Queensland, 4102, Australia
Local Institution
Clayton Victoria, 3168, Australia
Local Institution - 0004
Melbourne Victoria, 3000, Australia
Linear Clinical Research Ltd
Nedlands Western Australia, 6009, Australia
Cross Cancer Institute
Edmonton Alberta, T6G 1, Canada
Local Institution
Vancouver British Columbia, V5Z 4, Canada
Local Institution
Toronto Ontario, M5G 1, Canada
Local Institution
Greenfield Park Quebec, J4V 2, Canada
Local Institution - 0036
Montreal Quebec, H3T 1, Canada
Local Institution
Helsinki , 00180, Finland
Hopital Claude Huriez
Lille CEDEX , 59037, France
Local Institution
Lyon Cedex 08 , 69373, France
Local Institution
Marseille Cedex 5 , 13385, France
Hotel Dieu - Chu De Nantes
Nantes Cedex 01 , 44093, France
Local Institution
Paris , 75005, France
Local Institution
Toulouse , 31100, France
Local Institution - 0022
Villejuif , 94800, France
Local Institution
Essen , 45147, Germany
Local Institution
Heilbronn , 74078, Germany
Ospedale San Raffaele
Milano , 20132, Italy
IRCCS Istituto Nazionale Tumori Milano
Milano , 20133, Italy
Istituto Europeo Di Oncologia
Milano , 20141, Italy
Local Institution - 0009
Rozzano MI , 20089, Italy
Local Institution
Oslo , 0424, Norway
Oddzial Badan Wczesnych Faz
Warszawa Mazowieckie, 02-78, Poland
Local Institution - 0017
Barcelona , 08035, Spain
Local Institution
Madrid , 28040, Spain
Local Institution
Madrid , 28050, Spain
Local Institution
Solna , 171 6, Sweden

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

627

Study ID:

NCT02658890

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.